Download PDF
Kinder- und Jugendmedizin 2015; 15(05): 323-329
DOI: 10.1055/s-0038-1629284
Kinder- und Jugendrheumatologie
Schattauer GmbH

Neue Konzepte in der Behandlung der polyartikulären juvenilen idiopathischen Arthritis

New concepts in the treatment of polyarticular juvenile idiopathic arthritis
B. Hügle
1   Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen
› Author Affiliations
Further Information

Publication History

Eingereicht am: 01 June 2015

angenommen am: 08 June 2015

Publication Date:
27 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Die juvenile idiopathische Arthritis ist die häufigste chronische rheumatische Erkrankung im Kindesalter. Vor einer Generation war die Therapie beschränkt auf Erleichte-rung der Symptome und wenige, nebenwirkungsreiche Medikamente, sodass im Verlauf häufig körperliche Behinderungen und deutliche Einschränkungen der Lebensqualität bei erhöhter Sterblichkeit auftraten. Die Einfüh-rung neuer, hoch effektiver Medikamente in den letzten zwei Dekaden hat eine deutliche Besserung der Versorgung chronischer kindlicher Arthritiden ermöglicht. Eine frühe und möglichst vollständige Krankheitskontrolle lindert nicht nur die Krankheitslast, sondern scheint einen günstigen Effekt auf den Lang-zeitverlauf zu haben, mit einem möglichen „Window of Opportunity“ innerhalb der ersten Monate der Erkrankung. Viele Therapiekonzepte können von der rheumatoiden Arthritis übernommen werden. Leitlinien der Fachgesellschaften und neue Studien versu-chen, eine möglichst optimale Verwendung der neuen Therapiemöglichkeiten auszuloten.

Summary

Juvenile idiopathic arthritis is the most common chronic rheumatic disease in childhood. A generation ago, treatment was limited to alleviation of symptoms and a few medications fraught with adverse reactions, leading to functional impairment,significantly decreased quality of life over the course of the disease, and increased mortality. The introduction of new, highly effective medications in the last two decades has led to a marked improvement in the treatment of chronic arthritides in childhood. Early and, if possible, complete control of disease activity not only limits the burden of the disease but seems to have a beneficial effect on the long term course of the disease, with a possible “window of opportunity“ within the first few months of the disease. Many treatment concepts can be transferred from the study of rheumatoid arthritis. Guidelines of the professional societies and new studies try to establish an optimal use of the new treatment options available.

Schlüsselwörter

Juvenile idiopathische Arthritis - Biologika

Keywords

Juvenile idiopathic arthritis - biologic agents
 

  • Literatur

  • 1 Jacobs JC. Juvenile Rheumatoid Arthritis. Pediatric Rheumatology for the Practitioner. 2nd ed. New York, Berlin, Heidelberg: Springer; 1992: 231-359.
    Google Scholar
  • 2 Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007; 369: 767-778.
    CrossrefPubMedGoogle Scholar
  • 3 Petty RE, Southwood TR, Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. The Journal of rheumatology 2004; 31: 390-392.
    PubMedGoogle Scholar
  • 4 Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatric rheumatology online journal 2014; 12: 13
    CrossrefPubMedGoogle Scholar
  • 5 Ansell BM, Swann M. The management of chronic arthritis of children. The Journal of bone and joint surgery British volume 1983; 65: 536-543.
    PubMedGoogle Scholar
  • 6 Levinson JE, Wallace CA. Dismantling the pyramid. The Journal of rheumatology Supplemen 1992; 33: 6-10.
    Google Scholar
  • 7 Ruperto N, Martini A. Juvenile idiopathic arthritis and malignancy. Rheumatology 2014; 53: 968-974.
    CrossrefPubMedGoogle Scholar
  • 8 Guellac N, Niehues T. Interdisziplinäre S2-Therapieleitlinie der Juvenilen Idiopathischen Arthritis. Klinische Padiatrie 2008; 220: 392-402.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Dueckers G, Guellac N, Arbogast M. et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clinical immunology 2012; 142: 176-193.
    CrossrefPubMedGoogle Scholar
  • 10 Beukelman T, Patkar NM, Saag KG. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis care & researc 2011; 63: 465-482.
    Google Scholar
  • 11 Ringold S, Weiss PF, Beukelman T. et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis and rheumatism 2013; 65: 2499-2512.
    CrossrefPubMedGoogle Scholar
  • 12 Munro J. Recommendations for the Diagnosis and Management of Juvenile Idiopathic Arthritis. 2009: 1-38.
    Google Scholar
  • 13 Detert J, Bastian H, Listing J. et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Annals of the rheumatic diseases 2013; 72: 844-850.
    CrossrefPubMedGoogle Scholar
  • 14 Grigor C, Capell H, Stirling A. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-269.
    CrossrefPubMedGoogle Scholar
  • 15 Cush JJ. Early rheumatoid arthritis - is there a window of opportunity?. The Journal of rheumatology Supplement 2007; 80: 1-7.
    PubMedGoogle Scholar
  • 16 Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis and rheumatism 2006; 54: 2784-2792.
    CrossrefPubMedGoogle Scholar
  • 17 Puolakka K, Kautiainen H, Mottonen T. et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis and rheumatism 2005; 52: 36-41.
    CrossrefPubMedGoogle Scholar
  • 18 Rantalaiho V, Korpela M, Hannonen P. et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis and rheumatism 2009; 60: 1222-1231.
    CrossrefPubMedGoogle Scholar
  • 19 Emery P, Breedveld F, van der Heijde D. et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis and rheumatism 2010; 62: 674-682.
    CrossrefPubMedGoogle Scholar
  • 20 Kekow J, Moots RJ, Emery P. et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Annals of the rheumatic diseases 2010; 69: 222-225.
    CrossrefPubMedGoogle Scholar
  • 21 Resman-Targoff BH, Cicero MP. Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. The American journal of managed care 2010; 16 (Suppl. 09) Suppl S249-258.
    PubMedGoogle Scholar
  • 22 Martini A. Systemic juvenile idiopathic arthritis. Autoimmunity reviews 2012; 12: 56-59.
    CrossrefPubMedGoogle Scholar
  • 23 Nigrovic PA, Mannion M, Prince FH. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis and rheumatism 2011; 63: 545-555.
    CrossrefPubMedGoogle Scholar
  • 24 Gattorno M, Piccini A, Lasiglie D. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis and rheumatism 2008; 58: 1505-1515.
    CrossrefPubMedGoogle Scholar
  • 25 van Rossum MA, Fiselier TJ, Franssen MJ. et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis and rheumatism 1998; 41: 808-816.
    CrossrefPubMedGoogle Scholar
  • 26 van Rossum MA, van Soesbergen RM, Boers M. et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Annals of the rheumatic diseases 2007; 66: 1518-1524.
    CrossrefPubMedGoogle Scholar
  • 27 Vilca I, Munitis PG, Pistorio A. et al. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Annals of the rheumatic diseases 2010; 69: 1479-1483.
    CrossrefPubMedGoogle Scholar
  • 28 Geikowski T, Becker I, Horneff G, German BRCSG. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology 2014; 53: 1245-1249.
    CrossrefPubMedGoogle Scholar
  • 29 Albarouni M, Becker I, Horneff G. Predictors of response to methotrexate in juvenile idiopathic arthritis. Pediatric rheumatology online journal 2014; 12: 35
    CrossrefPubMedGoogle Scholar
  • 30 Tynjala P, Vahasalo P, Tarkiainen M. et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Annals of the rheumatic diseases 2011; 70: 1605-1612.
    CrossrefPubMedGoogle Scholar
  • 31 Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS. et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis and rheumatism 2012; 64: 2012-2021.
    CrossrefPubMedGoogle Scholar
  • 32 Wallace CA, Ringold S, Bohnsack J. et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. The Journal of rheumatology 2014; 41: 2459-2465.
    CrossrefPubMedGoogle Scholar
  • 33 Berard RA, Laxer RM. Early aggressive therapy for patients with juvenile idiopathic arthritis: are we there yet?. The Journal of rheumatology 2014; 41: 2343-2346.
    CrossrefPubMedGoogle Scholar
  • 34 Lehman TJ. The TREAT study - trial or tribulation?. The Journal of rheumatology 2014; 41: 1038-1039.
    CrossrefPubMedGoogle Scholar
  • 35 Ringold S, Weiss PF, Colbert RA. et al. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis care & research 2014; 66: 1063-1072.
    CrossrefPubMedGoogle Scholar
  • 36 Smolen JS, Landewe R, Breedveld FC. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the rheumatic diseases 2014; 73: 492-509.
    PubMedGoogle Scholar
  • 37 Smolen JS, Landewe R, Breedveld FC. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the rheumatic diseases 2010; 69: 964-975.
    CrossrefPubMedGoogle Scholar
  • 38 Consolaro A, Negro G, Lanni S. et al. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clinical and experimental rheumatology 2012; 30 (Suppl. 73) Suppl S157-162.
    PubMedGoogle Scholar
  • 39 Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nature reviews Rheumatology 2015; 11: 290-300.
    CrossrefPubMedGoogle Scholar
  • 40 Consolaro A, Verazza S, Gallo M. et al. PReS-FINAL-2132; Defining criteria for high disease activity in juvenile idiopathic arthritis: definition and validation of juvenile arthritis disease activity score cutoffs. Pediatric Rheumatology 2013; 11 (Suppl. 02) Suppl P145
    CrossrefGoogle Scholar